Skip to main content
Premium Trial:

Request an Annual Quote

Brian Brille, Michael Sullivan, Nicholas Nelson

Caris Life Sciences appointed Brian Brille as vice chairman, Michael Sullivan as chief commercial officer, and Nicholas Nelson as chief business officer. Brille will be responsible for corporate and business development, M&A, and capital markets. He has more than 25 years of experience as a senior financial services executive. Most recently, he was president of Asia Pacific for Bank of America Merrill Lynch. Before that, he was global head of corporate and investment banking at Bank of America. 

Before joining Caris, Sullivan was at Roche Diagnostics where he was most recently senior vice president, general manager, and business unit lifecycle leader of the company's core oncology franchise. He also held commercial leadership roles at Johnson & Johnson Ortho-Clinical Diagnostics and Abbott Laboratories' diagnostics division. 

Nelson was vice president of commercial and corporate development at Trovagene before joining Caris. He also spent 10 years at Illumina in R&D, technical service, and sales. 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.